# A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

> **NCT07023315** · PHASE3 · RECRUITING · sponsor: **Akeso** · enrollment: 760 (estimated)

## Conditions studied

- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** SOX chemotherapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07023315
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-14
- **Primary completion:** 2029-07
- **Final completion:** 2031-07
- **Target enrollment:** 760 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07023315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07023315, "A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07023315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*